Login / Signup

Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.

Paolo GisondiDavide GeatPatrizio ArmeniFrancesco BellinatoMartina MaurelliGiampiero Girolomoni
Published in: Expert opinion on biological therapy (2022)
The use of biosimilars was confirmed as a valuable pharmacoeconomic strategy to lower healthcare cost in patients with psoriasis.
Keyphrases
  • healthcare
  • rheumatoid arthritis
  • coronary artery disease
  • high dose
  • atopic dermatitis
  • systemic lupus erythematosus
  • low dose
  • health information
  • hidradenitis suppurativa
  • drug induced
  • social media